February 17, 2023
4 min watch
Save
VIDEO: Novel modulator platform may offer benefit as IOP-lowering agent
Issue: March 10, 2023
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective from Glaucoma 360 New Horizons Forum, Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, discusses study results for QLS-111.
QLS-111 is an ATP-sensitive potassium channel modulator that selectively targets episcleral venous pressure (EVP) in glaucoma.
“With this novel mechanism targeting EVP and an excellent safety profile, the potential of QLS-111 extends beyond primary open-angle glaucoma alone,” he said. “QLS-111 may provide a substantial benefit as an IOP-lowering agent for patients where EVP has limited maximum pharmacotherapy.”
Published by:
Sources/Disclosures
Collapse
Source:
Htoo T. Qlaris Bio. Presented at: Glaucoma 360 New Horizons Forum; Feb. 3, 2023; San Francisco.
Disclosures:
Htoo reports being the CEO and co-founder of Qlaris Bio and executive chairman and co-founder of Starlight Bio.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.